Huntington's Disease | Landscape & Forecast | Disease Landscape & Forecast

Publish date: August 2018

Login to access report

Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disease characterized by progressive chorea, dystonia, and cognitive decline. Current treatment is entirely focused on symptom management, and includes a cocktail of antidepressants, antipsychotics, and antiepileptics to control patients’ cognitive, behavioral, and neurological symptoms. Treatment for chorea is limited to tetrabenazine and Teva’s Austedo (deutetrabenazine), which launched in 2017. Although new HD treatments are an area of significant unmet need, the recent discontinuation of Teva’s pridopidine has left the late-stage pipeline devoid of candidates. However, the Phase II pipeline includes a variety of symptom-targeting and potential disease-modifying therapies, which could capitalize on the significant commercial opportunity that exists if they can demonstrate efficacy in HD patients.

QuestionsAnswered

  • How large is the diagnosed prevalent HD population in the United States and EU5, and how will it evolve through 2027?
  • What impact has the launch of Teva’s Austedo had on the HD treatment algorithm?
  • Which emerging therapies do neurologists consider the most promising for HD? Which are likely to launch by 2027?
  • What are the drivers and constraints in the HD drug market and how might these influence emerging therapy uptake?

Product Description

Niche & Rare Disease Landscape & Forecast: comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Commercial Outlook
      • Key Findings
      • Drivers and Constraints
        • What Factors Are Driving Sales in Huntington's Disease?
        • What Factors Are Constraining Sales in Huntington's Disease?
      • Dopamine-Depleting Agent-Specific Trends
      • Alternative Market Scenarios
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
      • Clinical Presentation and Symptomology in Adult-Onset Huntington's Disease
      • Juvenile Huntington's Disease
      • Key Pathways and Drug Targets
    • Epidemiology
      • Introduction
        • Key Findings
        • Overview
      • Epidemiology Populations
        • Diagnosed Prevalent Cases
        • Diagnosed Incident Cases of Huntington's Disease
        • Drug-Treated Cases of Huntington's Disease
    • Current Treatment
      • Key Findings
      • Diagnosis
        • Treatment Providers and Referral Patterns
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Dopamine-Depleting Agents
        • Antidepressants
        • Antipsychotics
        • Antiepileptic Mood Stabilizers
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Huntington's Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Huntington's Disease
        • Immunomodulators
        • Antisense Oligonucleotides
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Huntington's Disease
      • Key Discontinuations and Failures in Huntington's Disease
      • Patient Registries
        • Patient Organizations
      • Orphan-Drug Designation
        • Orphan-Drug Provisions: United States
        • Orphan-Drug Provisions: Europe
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Huntington's Disease Bibliography

Author(s): Laura Darnieder; Johnson Olabisi, MBBS, MSc

Laura Darnieder is a Business Insights Analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, where she is focused on providing market forecasts within the niche biopharmaceutical space. Prior to joining DRG, Laura earned a in Neuroscience from Tufts University Sackler School of Graduate Biomedical Sciences. Her research focused on the role of stress neuropeptides and inhibitory signaling in alcohol dependence and drug addiction. She also holds a , summa cum laude, in Psychobiology and Linguistics from Binghamton University (SUNY).

Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space. Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.